Adrenergic Agonists Flashcards
Catecholamines
general term for neurotransmitters/hormones in the sympathetic NS
named after their structure
catacholamines:
dopamine, neorepinephrine, epinephrine
4 Categories of Adrenergic Receptors
Alpha 1, Alpha 2, Beta 1, Beta 2, Dopamine
all are G-protein couples cell membrane bound receptors
Alpha 1 Receptors
Coupled with Gq proteins to phospholipase C
When activated, results in activation of protein kinas es
kinases activate other enzymes that result in physiologic actions–>see positive action
Alpha 2 Receptors
Couples with G1 proteins to adenylyl cyclase
when activated, results in inhibitory activity that decreases cAMP
decreased cAMP=reduces transduction of activating types of enzymatic messages
Beta Receptors
coupled with Gs proteins to adenylyl cyclase
increases conversion of ATP to cAMP
activated multiple kinases that activate additional enzymes leading to physiologic actions (stimulate kinase to result in some kind of effect)
Dopamine Receptors
D1=receptors stimulate adenylyl cyclase=increased cAMP
D2=receptors inhibit adenylyl cyclase=decreases cAMP
Variations in Adrenergic Receptor Response
selectivity
regulation
polymorphism
catecholamine metabolism
Adrenergic Receptor Selectivity
Sympathomimetic drugs–>able to bind to one subgroup of receptors without binding to other (a drug can bind to alpha 1 receptors but not alpha 2 or beta)
degree of binding is drug concentration dependent
low concentration= selective
high concentration=nonselective binding
Adrenergic Receptor Regulation
receptors up or down regulate over time which results to changes of the deugs response to sympathomimetic drugs
Desensitization
aka tachyphylaxis
occurs after long term exposure to catecholamines. Results in decrease responsiveness of that cell/tissue to additional stimulation
Mechanisms of Desensitization
altered transcription or translation of DNA/RNA
modification of receptors from interactions with enzymes or other proteins
long term exposure to agonist (tachypholyxis)
interactions or messages from other receptors
Desensitization for Theraputic Benefit
desensitixation of receptor desired
Ex. Drug Z binds to alpha 1 receptors and causes an exaggeration of the expected physiologic response
But the body doesnít like exaggerated drug-induced responses and wants to maintain homeostasis in the target organ, meaning less neurotransmitter will be available to bind to those alpha 1eceptors
This results in the actual desired effect of the drug, which is a decrease in alpha 1 activity in a specific target organ
Variations in Receptor Polymorphism
individuals amino acid differences aloter receptor response–>alter degree of susceptibility to desensitization and alter degree or responsiveness to drugs–>some theraputic drugs work in some pt’s but not others
Termination of NT’s action
- NE transporter (NET)–brings NE back to the presynaptic neuron
- movmenet of NE out of synaptic cleft into bloodstream
- Metabolism by COMT (catecholamine-O-methyltransferase)
Metabolism by monoamine axodase (MAO)
Norepinephrine Transporter (NET)
Removes 90% of released NE (most common way)
presynaptic pump that moves NE out of synapse and back into the neruon (NE will then be recycled or metabolized by MAO)
NET as Theraoutic Target
inhibits NET (atomoxetine and cocaine) leads to increased stimulation of adrenergic receptors
Catechol-O-methyl Transferase (COMT)
metabolizes all catecholamines–>terminates actions of NE, Epi, DA
drugs can inhibit COMT and prolong effect of the catecholamine
ex:Enatacopne (will inhibit COMT=increases DA)
Monoamine Oxidase (MAO)
metabolizes Monoamines (NE, EPi, Serotonin, DA) two forms A&B
Sympathomimetics
Drugs that mimic actions of NE, Epi, DA
2 forms-Direct & indirect agonists
Direct Agonist Sympathomimetics
structure allos for binding to adrenergic receptors resulting in activation
Indirect gonists
not interacting with receptor
cause release of stored catecholamines
inhibits reuptake of catechalomine already released
Structure of Sympathomimetics
similar structure to catecholamines, enough that NE receptors will allow it to bind
Benzene Ring Substitution
dding Hydroxyl groups–>maximizes a and b activity
adding hydroxyl to 1 reduces adrenergic potency
absence of OH will allow it to corss BBB and enter CNS
Amino Group Substitutions
increases Beta activity (decrease Alpha activity)
isopropyl on amino Nitrogen increases beta activity
Alpha Carbon Substitutions
block oxidation by MAO=prolonged duration of action (longer 1/2 life)
adding methyl group at alpha carbon increases ability to act as indirect sympathomimetics
Beta Carbon
less significant impact on activity
adding hydroxyl enables direct agonist activity
Sympathomimetic Effcts on Cardiovascular System
outcome is dependent on:
- selectivity for alpha and beta receptors
- agonist or antagonist
- action of body’s compensatory mechanism to maintain homeostasis
will effect HR, CO, BP, Venous return
Alpha 1 Cardiovascular Effects
Alpha 1 are in vascular beds ina rteries
activation of alpha 1=vasoconstriction=increase BP=the body will try and maintain normal range so it will slow HR and decrease CO (CO stays constant)
ex: Phenylephrine
Alpha 2 Cardiovascular Effects
in vascular beds and in CNS
Localy administration or HIGH dose=activation by alpha 2 agonists=vasoconstriction
Systemic administration=activation of central alpha 2 receptors=decrease in sympathetic activity=decrease in BP
ex:clonidide (to tx HTN)